Oncology & Cancer

FDA clears biomarker test for ovarian cancer

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

Oncology & Cancer

Nanotech'ed RNA drug reduces ovarian cancer tumors by 83 percent

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent—and stop ...

Oncology & Cancer

Cancer registry improves understanding of rare ovarian tumor

Ovarian granulosa cell tumors are a rare type of ovarian cancer that affect the ovaries and fallopian tubes, and can extend further into the pelvis and lymph nodes. Treatment typically follows the same guidelines as other ...

page 1 from 6